Skip to main content
TipRanks
Go Ultimate75% OFF

BioNxt Solutions (BNXT) AI Stock Analysis

16 Followers
TSE:BNXT

BioNxt Solutions

(CNQX:BNXT)

Select Model
Rating:37Underperform
Price Target:CAD 0.22â–¼(-6.67% Downside)
Action:reiterated
Date:11/20/26

The company faces an existential financial crisis with no revenue, insolvency, and accelerating cash burn. The stock is in a persistent downtrend across all timeframes, and negative earnings render valuation metrics useless. The overall score reflects a severely distressed, high-risk investment with no observable strengths.

Positive Factors
Drug-delivery platform focusA focused platform in transdermal and oral thin-film delivery gives BioNxt a defined technological direction within specialty pharmaceuticals. If product candidates advance, this concentration could support differentiated offerings and create opportunities to build value around its related intellectual property.
Negative Factors
Collapsed revenue baseThe absence of a consistent positive revenue base limits operating scale and makes future profitability difficult to assess. Without sustained commercial revenue, BioNxt may have less ability to absorb research, development, and corporate costs or finance growth internally over the next several quarters.

BioNxt Solutions (BNXT) vs. iShares MSCI Canada ETF (EWC)

-80%-60%-40%-20%0%20%40%TSE:BNXT-65.71%EWC+8.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 32.66M
Dividend Yield
―
Average Volume (3M)
37.04K
Price to Earnings (P/E)
-2.9
Beta (1Y)
0.23
Revenue Growth
―
EPS Growth
―
Country
Canada
Employees
25
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

BioNxt Solutions Business Overview & Revenue Model

Company Description

Headquartered in Vancouver, Canada, BioNxt Solutions Inc., established in 2017, operates as a bioscience company across Germany, Switzerland, Austria, Israel, and its home country. The firm focuses on developing innovative drug delivery systems, incl...

BioNxt Solutions Financial Statement Overview

Summary

Financial performance is critically distressed. Revenue has collapsed to near zero, gross profit is deeply negative, and the company is insolvent with negative equity. Cash burn is accelerating with no internal generation, indicating an existential crisis.

Income Statement

1Very Negative

Balance Sheet

1Very Negative

Cash Flow

1Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Dec 2022Mar 2022
Income Statement
Total Revenue-11.26K026.98K372.25K297.44K286.50K
Gross Profit-18.45K-10.90K26.98K372.25K195.62K199.48K
EBITDA-8.72M-6.04M-4.32M-6.48M-11.51M-19.19M
Net Income-10.55M-7.03M-5.31M-7.72M-12.38M-20.64M
Balance Sheet
Total Assets586.34K591.68K569.36K1.27M1.61M9.73M
Cash, Cash Equivalents and Short-Term Investments199.41K55.26K32.35K363.65K136.20K1.35M
Total Debt6.16M5.95M4.28M4.89M4.37M5.46M
Total Liabilities7.19M9.96M8.43M6.55M5.74M8.06M
Stockholders Equity-6.61M-9.37M-7.86M-5.28M-4.13M1.67M
Cash Flow
Free Cash Flow-3.53M-5.20M-3.03M-5.37M-6.23M-12.61M
Operating Cash Flow-3.53M-5.20M-3.03M-5.17M-6.23M-12.16M
Investing Cash Flow93.66K87.43K56.21K100.84K-3,858-5.31M
Financing Cash Flow3.17M5.13M2.64M5.29M5.02M16.23M

BioNxt Solutions Technical Analysis

Technical Analysis SentimentNegative
Last Price0.24

Price Trends

50DMA0.31Negative
100DMA0.32Negative
200DMA0.41Negative

Market Momentum

MACD-0.02Positive
RSI36.88Neutral
STOCH30.77Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BNXT, the sentiment is Negative. The current price of 0.24 is below the 20-day moving average (MA) of 0.27, below the 50-day MA of 0.31, and below the 200-day MA of 0.41, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 36.88 is Neutral, neither overbought nor oversold. The STOCH value of 30.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BNXT.

BioNxt Solutions Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:BNXT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:LABSTSE:LABS55NeutralCAD 23.49M-9.23-7.66%―-9.31%66.84%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:AVCNTSE:AVCN48NeutralCAD 11.42M-3.86-65.40%―-3.32%-34.15%
TSE:INNOTSE:INNO45NeutralCAD 8.05M-6.01-19.37%―-19.20%42.54%
TSE:ATLETSE:ATLE42NeutralCAD 37.30M-0.76-2099.75%―-96.13%88.13%
TSE:BNXTTSE:BNXT37UnderperformCAD 32.66M-2.91142.79%―――

* Healthcare Sector Average

Performance Comparison

-50%0%TSE:BNXTTSE:ATLETSE:LABSTSE:AVCNTSE:INNODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:BNXT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:BNXTBionxt Solutions Inc0.24-0.45-65.22%
TSE:ATLEWillow Biosciences0.08-0.07-46.67%
TSE:LABSMedipharm Labs (Otc)0.06-0.01-7.69%
TSE:AVCNAvicanna Inc0.09-0.15-64.58%
TSE:INNOInnocan Pharma Corporation1.79-11.00-86.00%

BioNxt Solutions Corporate Events

Business Operations and StrategyPrivate Placements and Financing

BioNxt Extends Convertible Debentures and Issues 16.9 Million Warrants

Neutral
Aug 22, 2026

BioNxt Solutions Inc., a bioscience company focused on advanced drug delivery platforms and diagnostic technologies for autoimmune, neurological and longevity-related conditions, operates R&D facilities in North America and Europe while targeting Eur...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 20, 2026